Related Experiment Video
Updated: Feb 24, 2026

Potentiodynamic Corrosion Testing
Published on: September 4, 2016
Cobalt Cardiomyopathy Secondary to Hip Arthroplasty: An Increasingly Prevalent Problem
Russel Tilney1, Melanie Roberta Burg2, Mark Adrian Sammut2
1Department of Medicine, Mater Dei Hospital, Msida, Malta.
Insights
Metal-on-metal hip implants can release cobalt, causing heart failure. Revision surgery to replace the implant resolved the patient's symptoms and improved heart function.
Area of Science:
- Biomaterials Science
- Cardiology
- Toxicology
Background:
- Total hip replacement with metal-on-metal components can lead to adverse local tissue reactions and systemic toxicity.
- Cobalt-chromium alloys are commonly used in hip arthroplasty, raising concerns about ion release and systemic effects.
Observation:
- A patient presented with worsening heart failure four years after bilateral complicated total hip replacement.
- Elevated cobalt blood levels and clinical presentation suggested implant-related toxicity.
- Intraoperative findings revealed biotribocorrosion on the hip arthroplasty components.
Findings:
- Revision surgery of the affected hip led to significant symptomatic improvement in heart failure (NYHA class III to I).
- Echocardiography demonstrated recovery of ejection fraction post-revision.
- Cobalt ions, similar to nanoparticles, exhibit cytotoxicity affecting neurological, thyroid, and cardiac systems.
Implications:
- Cobalt-induced cardiomyopathy is a potential complication of metal-on-metal hip arthroplasty.
- Arthroplasty revision is the definitive treatment for cobalt toxicity, as other therapies are unproven.
- Monitoring cobalt blood levels requires careful interpretation due to independent erythrocyte and serum dynamics.
Abstract:
A forty-year-old man experienced worsening heart failure four years following bilateral complicated total hip replacement. His condition was extensively worked up but no underlying pathology was immediately evident. Given the cobalt-chromium alloy component present in the hip arthroplasties, the raised cobalt blood levels, and a fitting clinical picture coupled with radiological findings, the patient underwent right hip revision. Evidence of biotribocorrosion was present on direct visualisation intraoperatively. The patient subsequently experienced symptomatic improvement (NYHA class III to class I) and echocardiography showed recovery of ejection fraction. Cobalt exists as a bivalent and trivalent molecule in circulation and produces a cytotoxicity profile similar to nanoparticles, causing neurological, thyroid, and cardiological pathology. Blood levels are not entirely useful as there is no identifiable conversion factor for levels in whole blood, serum, and erythrocytes which seem to act independently of each other. Interestingly cobalt cardiomyopathy is frequently compounded by other possible causes of cardiomyopathy such as alcohol and a link has been postulated. Definitive treatment is revision of the arthroplasty as other treatments are unproven.
More Related Videos
07:43In Vivo Quantification of Hip Arthrokinematics during Dynamic Weight-bearing Activities using Dual Fluoroscopy
Published on: July 2, 2021
09:51The Transition to an Anterior-Based Muscle Sparing Approach Improves Early Postoperative Function but is Associated with a Learning Curve
Published on: September 7, 2022
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VI: Nursing Management